Aura Biosciences Reports $45.6 Million Net Loss and Significant Asset Growth in Latest 10-Q

Aura Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $45.6 million for the quarter, compared to a loss of $27.0 million in the same period last year, reflecting an increase of 69% year-over-year. For the first half of 2026, the net loss was $79.3 million, up from $54.5 million in the first half of 2025. The increase in losses is attributed to higher operating expenses, which rose to $48.1 million for the quarter and $82.9 million for the six months, driven primarily by increased research and development costs associated with the ongoing Phase 3 trial of its lead candidate, bel-sar.

The company’s total assets surged to $348.1 million as of June 30, 2026, up from $169.4 million at the end of 2025. This increase was largely due to a significant rise in cash and marketable securities, which totaled $323.8 million, compared to $144.2 million at the end of the previous fiscal year. The substantial cash position was bolstered by a follow-on offering in May 2026, which generated approximately $280.8 million in net proceeds. This capital was partly utilized for a stock repurchase of 6.9 million shares at a cost of $39.1 million.

Operationally, Aura Biosciences is focused on advancing its bel-sar program, which is in late-stage clinical development for treating early choroidal melanoma. The company is also exploring additional indications, including metastases to the choroid and cancers of the ocular surface. The Phase 3 CoMpass trial is ongoing, and interim results from a Phase 1b/2 study in non-muscle invasive bladder cancer (NMIBC) have shown promising early clinical profiles, although the company plans to minimize resource allocation toward this program moving forward.

In terms of organizational changes, Aura announced a restructuring plan in August 2026 aimed at streamlining operations and focusing resources on its ocular oncology portfolio. This plan includes a workforce reduction of approximately 20%. Additionally, the company appointed new executives, including a Chief Operating Officer and a Chief Regulatory and Quality Officer, to strengthen its leadership team as it navigates its clinical development and commercialization strategies.

Looking ahead, Aura Biosciences anticipates continued operating losses as it invests heavily in research and development. The company expects its existing cash and marketable securities to fund operations into the first half of 2029, but it acknowledges the need for additional capital to support ongoing and future clinical trials. The ability to raise funds will be critical for the company’s growth and operational sustainability, particularly as it seeks to bring its innovative therapies to market.